STEVEN I SHERMAN to Double-Blind Method
This is a "connection" page, showing publications STEVEN I SHERMAN has written about Double-Blind Method.
Connection Strength
0.552
-
No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial. Diabetes Care. 2018 03; 41(3):620-622.
Score: 0.099
-
Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid. Eur J Cancer. 2017 04; 75:213-221.
Score: 0.094
-
Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes. Endocrine. 2017 Apr; 56(1):121-128.
Score: 0.093
-
Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer. Cancer. 2016 Dec 15; 122(24):3856-3864.
Score: 0.090
-
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021 08; 22(8):1126-1138.
Score: 0.032
-
Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib. Thyroid. 2021 08; 31(8):1226-1234.
Score: 0.031
-
Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT). Cancer. 2018 06 01; 124(11):2365-2372.
Score: 0.025
-
Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer. J Clin Endocrinol Metab. 2016 11; 101(11):4103-4109.
Score: 0.023
-
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014 Jul 26; 384(9940):319-28.
Score: 0.019
-
Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013 Oct 10; 31(29):3639-46.
Score: 0.018
-
Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. BMC Cancer. 2011 Aug 11; 11:349.
Score: 0.016
-
Single-dose rexinoid rapidly and specifically suppresses serum thyrotropin in normal subjects. J Clin Endocrinol Metab. 2007 Jan; 92(1):124-30.
Score: 0.011